Poherdy is the first FDA-approved interchangeable biosimilar to Perjeta for HER2-positive breast cancer, potentially expanding access and reducing costs. Approved for use in combination with ...
Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...
mRNA vaccines can enhance immunotherapy efficacy by activating the immune system, improving outcomes in hard-to-treat tumors. mRNA COVID-19 vaccines enhance immune responses, improving cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback